Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK pays $23 million up front for preclinical candidate

This article was originally published in Scrip

Executive Summary

Amplimmune has entered a broad alliance with GlaxoSmithKline to develop PD-1 targeting therapies for the treatment of cancer and other diseases. GSK will obtain exclusive worldwide rights to its lead product AMP-224 as well as other potential next-generation fusion proteins that target PD-1.

Topics

Related Companies

UsernamePublicRestriction

Register

SC009797

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel